2018年7月10日,
;91(2补充1)
文章
开放获取
皮肤纤维瘤的生物学
一致的建议设置研究重点
让-菲利普•但是,多米尼克·c·Pichard,Eric h . Legius,皮埃尔Wolkenstein,罗伯特·m·Lavker,Jaishri o·布莱克利正在,文森特·m·Riccardi,Verma拉德·k .,艾萨克·布劳内尔,陆问:勒
第一次出版2018年7月9日,
DOI: https://doi.org/10.1212/WNL.0000000000005788
让-菲利普•但是
的皮肤病(J.P.B.,L.Q.L.), UT Southwestern Medical Center, Dallas, TX; Dermatology Branch (D.C.P., I.B.), Center for Cancer Research, National Cancer Institutes of Health, Bethesda, MD; Human Genetics Department (E.H.L.), University of Leuven, Belgium; Division Cancer Immunity Transplantation Infections (P.W.), Paris Est Créteil University, France; Department of Dermatology (R.M.L.), Northwestern University, Chicago, IL; Department of Neurology (J.O.B., S.K.V.), The Neurofibromatosis Therapeutic Acceleration Program, The Johns Hopkins University School of Medicine, Baltimore, MD; and The NF Institute (V.M.R.), La Crescenta, CA.
多米尼克·c·Pichard
的皮肤病(J.P.B.,L.Q.L.), UT Southwestern Medical Center, Dallas, TX; Dermatology Branch (D.C.P., I.B.), Center for Cancer Research, National Cancer Institutes of Health, Bethesda, MD; Human Genetics Department (E.H.L.), University of Leuven, Belgium; Division Cancer Immunity Transplantation Infections (P.W.), Paris Est Créteil University, France; Department of Dermatology (R.M.L.), Northwestern University, Chicago, IL; Department of Neurology (J.O.B., S.K.V.), The Neurofibromatosis Therapeutic Acceleration Program, The Johns Hopkins University School of Medicine, Baltimore, MD; and The NF Institute (V.M.R.), La Crescenta, CA.
Eric h . Legius
的皮肤病(J.P.B.,L.Q.L.), UT Southwestern Medical Center, Dallas, TX; Dermatology Branch (D.C.P., I.B.), Center for Cancer Research, National Cancer Institutes of Health, Bethesda, MD; Human Genetics Department (E.H.L.), University of Leuven, Belgium; Division Cancer Immunity Transplantation Infections (P.W.), Paris Est Créteil University, France; Department of Dermatology (R.M.L.), Northwestern University, Chicago, IL; Department of Neurology (J.O.B., S.K.V.), The Neurofibromatosis Therapeutic Acceleration Program, The Johns Hopkins University School of Medicine, Baltimore, MD; and The NF Institute (V.M.R.), La Crescenta, CA.
皮埃尔Wolkenstein
的皮肤病(J.P.B.,L.Q.L.), UT Southwestern Medical Center, Dallas, TX; Dermatology Branch (D.C.P., I.B.), Center for Cancer Research, National Cancer Institutes of Health, Bethesda, MD; Human Genetics Department (E.H.L.), University of Leuven, Belgium; Division Cancer Immunity Transplantation Infections (P.W.), Paris Est Créteil University, France; Department of Dermatology (R.M.L.), Northwestern University, Chicago, IL; Department of Neurology (J.O.B., S.K.V.), The Neurofibromatosis Therapeutic Acceleration Program, The Johns Hopkins University School of Medicine, Baltimore, MD; and The NF Institute (V.M.R.), La Crescenta, CA.
罗伯特·m·Lavker
的皮肤病(J.P.B.,L.Q.L.), UT Southwestern Medical Center, Dallas, TX; Dermatology Branch (D.C.P., I.B.), Center for Cancer Research, National Cancer Institutes of Health, Bethesda, MD; Human Genetics Department (E.H.L.), University of Leuven, Belgium; Division Cancer Immunity Transplantation Infections (P.W.), Paris Est Créteil University, France; Department of Dermatology (R.M.L.), Northwestern University, Chicago, IL; Department of Neurology (J.O.B., S.K.V.), The Neurofibromatosis Therapeutic Acceleration Program, The Johns Hopkins University School of Medicine, Baltimore, MD; and The NF Institute (V.M.R.), La Crescenta, CA.
Jaishri o·布莱克利正在
的皮肤病(J.P.B.,L.Q.L.), UT Southwestern Medical Center, Dallas, TX; Dermatology Branch (D.C.P., I.B.), Center for Cancer Research, National Cancer Institutes of Health, Bethesda, MD; Human Genetics Department (E.H.L.), University of Leuven, Belgium; Division Cancer Immunity Transplantation Infections (P.W.), Paris Est Créteil University, France; Department of Dermatology (R.M.L.), Northwestern University, Chicago, IL; Department of Neurology (J.O.B., S.K.V.), The Neurofibromatosis Therapeutic Acceleration Program, The Johns Hopkins University School of Medicine, Baltimore, MD; and The NF Institute (V.M.R.), La Crescenta, CA.
文森特·m·Riccardi
的皮肤病(J.P.B.,L.Q.L.), UT Southwestern Medical Center, Dallas, TX; Dermatology Branch (D.C.P., I.B.), Center for Cancer Research, National Cancer Institutes of Health, Bethesda, MD; Human Genetics Department (E.H.L.), University of Leuven, Belgium; Division Cancer Immunity Transplantation Infections (P.W.), Paris Est Créteil University, France; Department of Dermatology (R.M.L.), Northwestern University, Chicago, IL; Department of Neurology (J.O.B., S.K.V.), The Neurofibromatosis Therapeutic Acceleration Program, The Johns Hopkins University School of Medicine, Baltimore, MD; and The NF Institute (V.M.R.), La Crescenta, CA.
Verma拉德·k .
的皮肤病(J.P.B.,L.Q.L.), UT Southwestern Medical Center, Dallas, TX; Dermatology Branch (D.C.P., I.B.), Center for Cancer Research, National Cancer Institutes of Health, Bethesda, MD; Human Genetics Department (E.H.L.), University of Leuven, Belgium; Division Cancer Immunity Transplantation Infections (P.W.), Paris Est Créteil University, France; Department of Dermatology (R.M.L.), Northwestern University, Chicago, IL; Department of Neurology (J.O.B., S.K.V.), The Neurofibromatosis Therapeutic Acceleration Program, The Johns Hopkins University School of Medicine, Baltimore, MD; and The NF Institute (V.M.R.), La Crescenta, CA.
艾萨克·布劳内尔
的皮肤病(J.P.B.,L.Q.L.), UT Southwestern Medical Center, Dallas, TX; Dermatology Branch (D.C.P., I.B.), Center for Cancer Research, National Cancer Institutes of Health, Bethesda, MD; Human Genetics Department (E.H.L.), University of Leuven, Belgium; Division Cancer Immunity Transplantation Infections (P.W.), Paris Est Créteil University, France; Department of Dermatology (R.M.L.), Northwestern University, Chicago, IL; Department of Neurology (J.O.B., S.K.V.), The Neurofibromatosis Therapeutic Acceleration Program, The Johns Hopkins University School of Medicine, Baltimore, MD; and The NF Institute (V.M.R.), La Crescenta, CA.
陆问:勒
的皮肤病(J.P.B.,L.Q.L.), UT Southwestern Medical Center, Dallas, TX; Dermatology Branch (D.C.P., I.B.), Center for Cancer Research, National Cancer Institutes of Health, Bethesda, MD; Human Genetics Department (E.H.L.), University of Leuven, Belgium; Division Cancer Immunity Transplantation Infections (P.W.), Paris Est Créteil University, France; Department of Dermatology (R.M.L.), Northwestern University, Chicago, IL; Department of Neurology (J.O.B., S.K.V.), The Neurofibromatosis Therapeutic Acceleration Program, The Johns Hopkins University School of Medicine, Baltimore, MD; and The NF Institute (V.M.R.), La Crescenta, CA.
做出评论
看到评论
文摘
客观的一群皮肤学专家、遗传学、神经科学和再生医学合作总结当前知识定义的因素导致皮肤的纤维神经瘤(cNF)开发并提供一致的建议未来的研究优先级获得一个改进的cNF的生物学的理解。
方法组员回顾了cNF发表和未发表的数据,通过文献检索相关疾病,定义一组认为cNF发病机理的关键,重点和发展建议在一系列的共识会议。
结果五个特定主题领域被确定为相关提供一个增强的理解生物学cNF:(1)定义起源的人类细胞;(2)理解微环境的作用,关注神经细胞,肥大细胞,成纤维细胞;(3)定义的遗传和分子之间的差异cnf,注重在规模和数量;(4)理解如果性激素cNF开发或发展至关重要;(5)确定挑战建立体外和体内模型代表人类cNF。
结论cNF生物学的复杂性源于其异质性在多个水平包括遗传、空间参与,时间发展,细胞成分。cNF我们提出一个统一的工作模型,构建了一个框架来解决关键问题cNF,回答时,将提供必要的理解cNF生物学疗法允许有意义的发展。
术语表
- 平静=
- 浅褐色斑点;
- cNF=
- 皮肤纤维神经瘤;
- ECM=
- 细胞外基质;
- 差距=
- GTPase-activating蛋白质;
- 对于=
- 恶性周边神经鞘肿瘤;
- 氟化钠=
- neurofibroma-associated成纤维细胞;
- NF1=
- 神经纤维瘤病1型;
- pNF=
- 丛状神经纤维瘤;
- SKP=
- 烹饪和前驱细胞;
- TGF-β=
- 肿瘤生长factor-β
脚注
- 收到了2017年11月1日。
- 接受的最终形式2018年4月9日。
- ©2018年作者(年代)。发表的Wolters Kluwer健康,公司代表美国神经病学学会。首页
这是一个开放的分布式根据文章知识共享归属许可4.0 (CC),它允许无限制的使用、分配和复制在任何媒介,提供最初的工作是正确引用。
信:快速的网络通信
你可能也会感兴趣
广告
主题讨论
提醒我
推荐的文章
- 观点和评论
消除障碍个性化医疗从神经纤维瘤病1型学习
戴维·h·古特曼等。
首页神经学,2014年6月27日 - 文章
联系NF1的良性和恶性周边神经鞘肿瘤t·塔克·Wolkenstein j . Revuz et al。
首页神经学,2005年7月25日 - 生物标记物
Genotype-Phenotype相关性神经纤维瘤和潜在的临床应用奇Bettegowda之一Meena Upadhayaya, d . Gareth Evans et al。
首页神经学,2021年7月6日 - 文章
皮肤纤维瘤目前临床和病理问题
皮埃尔Wolkenstein尼古拉•Ortonne Jaishri o·布莱克利正在等。
首页神经学、09年7月,2018年